Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Browse Research
  • Browse News
  • About Our Research
  • Transplant Enews

  • Research and News
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020
- Collapse

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • Review: Scientific advances in myelodysplastic syndromes

    March 2019

    Löwenberg B, Blood Journal – A series of review articles in the Blood Journal provides a comprehensive overview of the current landscape of MDS, highlighting advances in biological and clinical science.

    Read More

  • Neurocognition stabilizes after HCT for patients for sickle cell disease-induced cognitive decline

    February 2019

    In addition to the risk of stroke and cognitive decline, children with sickle cell disease (SCD) may lose approximately one IQ point per year on a full scale IQ (FSIQ) test. For the first time, researchers report stabilization of IQ and central nervous system (CNS) outcomes after unrelated allogeneic hematopoie

    Read More

  • How I treat Philadelphia chromosome positive ALL

    January 2019

    The introduction of effective novel agents is swiftly changing management of patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). In this edition of the “How I treat…” series in the Blood Journal , the author uses case studies to address questions about Ph+ ALL treatment deci

    Read More

  • Allogeneic HCT should be considered as first-line treatment for SAA

    September 2018

    Researchers suggest the initial treatment guidelines for patients newly diagnosed with severe aplastic anemia (SAA) should be revised. They recommend allogeneic hematopoietic cell transplantation (HCT) as the first-line therapy and HLA typing for all newly diagnosed patients prior to starting treatment. (Georges GE, et al. Blood Advances)

    Learn why the researchers are recommending the new first-line treatment strategy

    Read More

  • Consensus Statement on HCT Late Effects Screening Guidelines in Hemoglobinopathies

    June 2018
    Shenoy S, et al. Biol Blood Marrow Transplant – An international panel of HCT experts has updated late effects screening guidelines for pediatric transplantation for hemoglobinopathies, focusing on sickle cell disease and thalassemia.

    Read More

  • Second HCT Effective for Subset of Relapsing Children with Acute Leukemia

    April 2018
    Yaniv I, et al. Biol Blood Marrow Transplant – This multi-center study of 373 children who relapsed after allogeneic hematopoietic cell transplantation (HCT) revealed several prognostic factors predicting overall survival and leukemia-free survival in a subset of these patients.

    Read More

  • Study Identifies Key Factors Influencing the Decision to Pursue HCT for Sickle Cell Disease

    January 2018
    Khemani K, et al. Biol Blood Marrow Transplant – Currently, hematopoietic stem cell transplant (HCT) is the only treatment for sickle cell disease (SCD) with a curative intent.

    Read More

  • Personalized HCT Prognostic Risk Scores Identified for Children with Acute Leukemias

    January 2018
    Bitan M, et al. Biol Blood Marrow Transplant – Researchers analyzed outcomes of children with acute myeloid (AML, n=790) and acute lymphoblastic leukemia (ALL, n=1,096) who survived for at least 1 year in remission after hematopoietic cell transplantation (HCT) have developed personalized long-term prognostic scoring systems for these patients.

    Read More

  • HCT Significantly Improves Quality of Life in Children with Sickle Cell Disease

    December 2017
    Bernaudin F, et al. ASH abstract oral presentation, December 2017 – Children with sickle cell disease (SCD) have significantly better physical health and school functioning after transplantation than do those receiving chronic transfusion, according to results of a donor/no donor study of 67 patients with SCD.

    Read More

  • Study Identifies Optimal Therapies for Relapsed Pediatric AML

    September 2017
    Karlsson L, et al. Br J Haematol – A large-scale study of children with relapsed acute myeloid leukemia (AML) has found that intensive re-induction therapy followed by hematopoietic cell transplantation (HCT) in second complete remission (CR2) is the best available treatment for the majority of these patients.

    Read More

  • 30% of Very Young HCT Recipients Experience One or More Late Effects

    June 2017
     Vrooman LM, et al. Biol Blood Marrow Transplant - This multi-center study showed that children under 3 years old who undergo HCT are at high risk for late effects. After 1 year, 30% had developed 1 or more organ toxicity or transplant-related complication.

    Read More

  • Alternative Donor HCT Better than Immunosuppressive Therapy in Pediatric SAA

    November 2016
    Choi YB, et al. Bone Marrow Transplant – This retrospective single-center study of children and adolescents with severe aplastic anemia (SAA) found that upfront hematopoietic cell transplantation (HCT) using alternative donors resulted in significantly better outcomes compared to both salvage HCT and upfront immunosuppressive treatment (IST).

    Read More

  • Improved Survival Over Time in Pediatric HCT

    July 2016
    Svenberg P, et al. Ped Transplant – A long-term study of pediatric allogeneic transplants found that outcomes improved over time, with significantly improved overall survival (OS) in transplants performed in the 2003-2013 time period compared to those performed in 1992-2002.

    Read More

  • Better HCT Outcomes Over Time in Children and Adolescents

    March 2016
    Brissot E, et al. Bone Marrow Transplant – Major advances in supportive care and HCT practice in the past decade have resulted in expanded indications and a significant survival benefit for pediatric patients undergoing allogeneic HCT, according to a single-center study of 250 children and adolescents transplanted between 1983 and 2010.

    Read More

  • Low Incidence of Late Cardiovascular Complications after Pediatric HCT

    February 2016
    Duncan CN, et al. BMT Tandem Meetings abstract oral presentation, February 2016 – Serious cardiovascular (CV) late effects are uncommon in pediatric transplant survivors, according to a multi-center study of 661 children who underwent hematopoietic cell transplantation (HCT) for hematologic malignancy between 1995 and 2008.

    Read More

  • Children Under 3 Years Old Undergoing HCT Require Long-Term Monitoring for Late Effects

    February 2016
    Vrooman L, et al. BMT Tandem Meetings abstract oral presentation, February 2016 – A study of myeloablative hematopoietic cell transplantation (HCT) performed in children under 3 years old has found that although transplant-related mortality at 10 years is only 5%, recipients require monitoring for late complications.

    Read More

  • Children’s Oncology Group: Long-Term Follow-Up Guidelines After Pediatric HCT

    February 2016
    Chow EJ, et al. Biol Blood Marrow Transplant – The Children’s Oncology Group (COG) has updated its Long-Term Follow-Up Guidelines for survivors of childhood, adolescent, and young adult cancer, including those undergoing autologous or allogeneic hematopoietic cell transplantation (HCT) and malignant and non-malignant diseases.

    Read More

  • Early HCT for SCD in Children is Preferred Therapy Prior to Onset of SCD Complications

    December 2015
    Satwani P, et al. ASH abstract oral presentation, December 2015 – Hematopoietic cell transplantation (HCT) to treat sickle cell disease (SCD) can result in up to 96% survival at two years, according to research results presented at the ASH Annual Meeting.

    Read More

  • Meeting the Needs of HCT Recipients Transitioning from Childhood to Adulthood

    December 2015
    Cupit MC, et al. Bone Marrow Transplant – In this review, the authors use clinical vignettes to discuss the focused and specific survivorship needs of the growing pediatric and adolescent and young adult (AYA) populations after hematopoietic cell transplantation (HCT).

    Read More

  • Review: HLA-Identical Sibling HCT to Treat Sickle Cell Disease in Children

    November 2015
    Walters MC, et al. Biol Blood Marrow Transplant – In this of review of HLA-identical sibling transplantation to treat sickle cell disease (SCD) in children, the authors assess the risk of mortality and compare published rates of survival in SCD patients treated and not treated by HCT.

    Read More

  • Improved Outcomes in Alternative Donor HCT for Fanconi Anemia

    July 2015
    MacMillan ML, et al. Blood — This prospective study of 130 patients (age range 1-48) transplanted for Fanconi anemia (FA) has shown that over a period of 10 years, transplant toxicity has decreased and engraftment has improved, resulting in a 5-year overall survival (OS) of 58% (95% CI, 49-59).

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2021 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • ASH 2017
  • AML
  • MDS
  • Lymphomas and CLL
  • Older Patient HCT
  • Sickle Cell Disease
  • Post-Transplant
  • GVHD
  • Patient Eligibility
  • CIBMTR Publications
  • Cord Blood
  • Pediatric HCT
  • ALL
  • CML
  • Multiple Myeloma
  • Neuroblastoma
  • Non-Malignant Disorders
  • HLA Matching
  • Preparative Regimens
  • BMT CTN Publications
  • Unrelated Donor HCT
  • ASH 2018
  • ASH 2020